EMA Advises Ifosfamide Solutions’ Benefits Outweigh Risks as Cancers Treatment

The European Medicines Agency (EMA)’s safety committee has said that ifosfamide administered via infusion has benefits that outweigh the risks for treating various cancers, including those with solid tumors, and blood cancers, such as lymphomas.

The agency reviewed the matter after two studies suggested that the risk of encephalopathy from ifosfamide supplied in solution forms is higher than with the powder form.

The EMA said that, based on the data, the increased risk of brain disorders couldn’t be confirmed or excluded, and suggested updating the listed side effects to note the risk and the need to monitor patients closely.